qinlock
deciphera pharmaceuticals (netherlands) b.v. - ripretinib - tumori gastrointestinalnog stroma - antineoplastična sredstva - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.
sprycel
bristol-myers squibb pharma eeig - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastična sredstva - Спрайсел indiciran za liječenje pedijatrijska bolesnika:prvi put otkrivene philadelphia kromosoma-pozitivan kroničnog миелоидного leukemije u fazi kroničnog (ph+ kml cp) ili ph+ kml usp stabilnost ili netrpeljivosti ranije terapiju, uključujući imatinib. nedavno dijagnosticiran, ph+ akutne limfoblastične leukemije (all) u kombinaciji s kemoterapijom. Спрайсел indiciran za liječenje odraslih bolesnika s je prvi put dijagnosticiran philadelphia kromosoma-pozitivan (ph+) kronične миелоидного leukemije (kml) u fazi kroničnog;kronične, ubrzani ili eksplozije fazi kml s inzulinska ili netrpeljivosti ranije terapiju, uključujući imatinib мезилат;ph+ akutne limfoblastične leukemije (all) i лимфоидных eksplozije kml pri otpornost ili nepodnošenje prethodne terapije. Спрайсел indiciran za liječenje pedijatrijska bolesnika s je prvi put dijagnosticiran ph+ kml u kroničnu fazu (ph+ kml-cp) ili ph+ kml-cp s tolerancije ili netrpeljivosti ranije terapiju, uključujući imatinib.
dasatinib accordpharma
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastična sredstva - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.
iclusig
incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. pogledajte odjeljke 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.
tasigna 200 mg/1 kapsula kapsula, tvrda
novartis ba d.o.o. - nilotinib - kapsula, tvrda - 200 mg/1 kapsula - 1 kapsula, tvrda sadrži: 200 mg nilotiniba (u obliku nilotinibhidrohlorid, monohidrata)
tasigna 200 mg/1 kapsula kapsula, tvrda
novartis ba d.o.o. - nilotinib - kapsula, tvrda - 200 mg/1 kapsula - jedna kapsula sadrži: 200 mg nilotiniba (u obliku hidrohlorid monohidrata)
tasigna 150 mg/1 kapsula kapsula, tvrda
novartis ba d.o.o. - nilotinib - kapsula, tvrda - 150 mg/1 kapsula - 1 kapsula sadrži: 150 mg nilotiniba (u obliku nilotinibhidrohlorid, monohidrata)
tasigna 200mg kapsula, tvrda
"novartis pharma services ag" dio stranog druŠtva podgorica - nilotinib - kapsula, tvrda - 200mg
tasigna 200mg kapsula, tvrda
"novartis pharma services ag" dio stranog druŠtva podgorica - nilotinib - kapsula, tvrda - 200mg
nitinab 150 mg/1 kapsula kapsula, tvrda
nobel lijek d.o.o. sarajevo - nilotinib - kapsula, tvrda - 150 mg/1 kapsula - jedna kapsula sadrži nilotinib hidrohlorid u količini ekvivalentnoj 150mg nilotiniba kao aktivne supstance.